Source: Annual Congress 2002 - Asthma - Therapy and management -1
Disease area: Airway diseases

Abstract

The introduction of budesonide/formoterol (Symbicort® Turbuhaler®) for the treatment of asthma makes it possible to adjust doses of both inhaled corticosteroid and long-acting β2-agonist using a single inhaler. The ATACO study is comparing the benefits of an adjustable maintenance treatment with fixed-dose asthma treatment on symptom control, quality of life and treatment costs. This is a 16 week, randomised, parallel-group, open study involving 4019 patients with mild-to-moderate persistent asthma (57% female) with a mean age (±]SEM) of 38±]10 years. During a 4-week run in period, all patients receive budesonide/formoterol (160/4.5 μg) in a single inhaler, two inhalations bid. Thereafter, patients in the fixed-dose management group continue to receive budesonide/formoterol bid for 12 weeks while ATACO patients are stepped down to one inhalation bid. In cases of predefined asthma worsenings (increase in symptoms or terbutaline use, or decrease in morning PEF) patients in the ATACO group temporarily increase their dose to two or four inhalations bid until PEF values return to previous values and symptoms resolve. Asthma worsenings in the fixed-dose management group are treated without changing the daily budesonide/formoterol dose. The results of this study will show whether individualised tailored dosing with budesonide/formoterol in a single inhaler achieves equivalent asthma control to the fixed dosing regimen.

Rating:

Share or cite this content

Citations should be made in the following way:
P. Kardos, B. Brueggenjuergen, A. Baare, W. Meyer-Sabellek, K. Richter, C. Vogelmeier, S. N. Willich, R. Buhl (Frankfurt, Berlin, Wedel, Grosshansdorf, Marburg, Mainz, Germany). The ATACO study: adjustable maintenance therapy with budesonide and formoterol in a single inhaler. Eur Respir J 2002; 20: Suppl. 38, 377

Member's Comments

No comment yet.

Related content which might interest you: Adjustable maintenance treatment of asthma with budesonide and formoterol in a single inhaler Source: Eur Respir J 2002; 20: Suppl. 38, 397s Year: 2002 Efficacy, safety and cost of budesonide/formoterol in a single inhaler compared with budesonide plus formoterol as separate inhalers Source: Eur Respir J 2002; 20: Suppl. 38, 43s Year: 2002 Cost-effectiveness of budesonide and formoterol in a single inhaler compared to fluticasone in the treatment of asthma Source: Eur Respir J 2001; 18: Suppl. 33, 157s Year: 2001 Scientific rationale for using a single inhaler for asthma control by comparison of the effectiveness and safety of formoterol/budesonide turbuhaler as physician-guided adjustable maintenance dosing regimen versus formoterol/budesonide given as fixed dose of twice daily therapy in the management of bronchial asthma Source: Annual Congress 2009 - Aspects of clinical asthma Year: 2009 Early and sustained benefits of budesonide and formoterol in a single inhaler vs fluticasone in moderate asthma Source: Eur Respir J 2001; 18: Suppl. 33, 157s Year: 2001 Add-on LABA in a separate inhaler as asthma step-up therapy versus increased dose of ICS or ICS/LABA combination inhaler Source: ERJ Open Res 2016: 00106-2015 Year: 2016 Budesonide and formoterol in a single inhaler is safe and effective in the treatment of asthma Source: Eur Respir J 2001; 18: Suppl. 33, 159s Year: 2001 Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone Source: Eur Respir J 2001; 18: 262-268 Year: 2001 Efficacy and safety of new formulation of fluticasone propionate/salmeterol delivered via a HFA pMDI inhaler in patients with asthma Source: Virtual Congress 2020 – Asthma inhalers: devices and adherence studies Year: 2020 Effectiveness of adjustable maintenance dosing and fixed dosing with budesonide/formoterol single inhaler in a multi-ethnic asthma population Source: Eur Respir J 2004; 24: Suppl. 48, 311s Year: 2004 Fluticasone/formoterol combined in a single aerosol inhaler vs budesonide/formoterol for the treatment of asthma: A non-inferiority trial Source: Annual Congress 2011 - Asthma: control and treatment Year: 2011 Budesonide/formoterol in a single inhaler improves asthma control more effectively than a higher dose of fluticasone Source: Eur Respir J 2001; 18: Suppl. 33, 21s Year: 2001 Beclometasone/formoterol administered via extrafine dry powder inhaler in controlled asthmatic patients: Comparison with pMDI and beclometasone monotherapy Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012 Does Clickhaler match the Turbuhaler for efficacy of inhaled budesonide? Source: Eur Respir J 2005; 26: Suppl. 49, 339s Year: 2005 Steroid inhaler dose reduction in comparison with montelukast discontinuation in asthma patients controlled by steroid inhaler and montelukast Source: International Congress 2018 – New developments in the treatment of asthma Year: 2018 Scientific rationale for inhaled combination therapy with long-acting β2-agonists and corticosteroids Source: Eur Respir J 2002; 19: 182-191 Year: 2002 A comparison of the efficacy of salmeterol/fluticasone propionate combination (SF) with beclometasone dipropionate (BDP) delivered via metered dose inhaler (MDI) in patients not well controlled on bronchodilators alone Source: Eur Respir J 2001; 18: Suppl. 33, 53s Year: 2001 Budesonide/formoterol in a single inhaler once or twice daily provides better asthma control than inhaled fluticasone or budesonide alone in patients with moderate persistent asthma Source: Eur Respir J 2002; 20: Suppl. 38, 387s Year: 2002 Healthcare costs are reduced when asthma is treated with budesonide and formoterol in a single inhaler compared with the same medication via separate inhalers Source: Eur Respir J 2001; 18: Suppl. 33, 54s Year: 2001 Budesonide and formoterol in a single inhaler is more effective than a higher dose of inhaled corticosteroid in mild-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 159s Year: 2001